A Study of the Effect of First Line Treatment With Paclitaxel and Myocet in Combination With Herceptin on Overall Tumor Response in Patients With Metastatic or Locally Advanced Breast Cancer and HER2 Overexpression.

Trial Profile

A Study of the Effect of First Line Treatment With Paclitaxel and Myocet in Combination With Herceptin on Overall Tumor Response in Patients With Metastatic or Locally Advanced Breast Cancer and HER2 Overexpression.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2015

At a glance

  • Drugs Trastuzumab (Primary) ; Doxorubicin liposomal; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 11 Mar 2015 According to ClinicalTrials.gov, protocol has been amended from phase I to phase I/II and time-frame of primary endpoint has changed from 4 months to baseline (BL), Weeks 7, 13, 19, every 8 weeks thereafter until end of study (for up to 3 years); treatment arms have been amended as well.
    • 24 Dec 2013 New source identified and integrated (ClinicalTrials.gov; NCT02015676).
    • 16 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top